Premium
Where does O 6 ‐methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?
Author(s) -
Weller Michael
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31244
Subject(s) - temozolomide , methyltransferase , o 6 methylguanine dna methyltransferase , glioblastoma , methylation , dna methylation , medicine , dna methyltransferase , cancer research , biomarker , dna , promoter , oncology , gene , biology , genetics , gene expression
Methylation of the promoter region of the O 6 ‐methylguanine DNA methyltransferase ( MGMT ) gene has emerged as the first—and so far the only—predictive biomarker for glioblastoma. Challenges in establishing a reliable assay to interrogate MGMT promoter methylation status and the lack of therapeutic alternatives to alkylating agent chemotherapy remain hurdles in the global implementation of MGMT testing as part of the standard of care.